ACLY and cardiovascular disorder: In fact, clinical trial data have shown that bempedoic acid, an ACLY inhibitor, reduces low-density lipoprotein cholesterol (LDL-c) levels and subsequently lowers cardiovascular disease (CVD) risk [12,13].